1. Exclusive licensing agreement with Eli Lilly enables Lupin to commercialize and distribute Cialis©
  2. Jubilant Life to buy Triad Isotopes' radio-pharmacy business
  3. SkinCeuticals announces partnership with ReSurge International
  4. AstraZeneca has paid $45 million and committed to up to $2.1 billion in milestones to team with Pieris Pharmaceuticals
  5. Sosei pays £35M stake, with future buyout option, for British biotech MiNA
  6. LivaNova buys Caisson Interventional, a Minnesota-based heart valve maker, for $72 million.
  7. Sanofi inks €250M bispecific small molecule diabetes deal
  8. Takeda pens GammaDelta Therapeutics $100M pact, with M&A option
  9. Prolific dealmakers Akebia and Vifor pen anemia drug pact
  10. Bioverativ to buy True North for $400M upfront
  11. Heptares nabs $5M from Teva for new migraine molecule
  12. OSE Immunotherapeutics inks $10.7M deal with Servier to develop and commercialize its interleukin-7 antagonist targeting autoimmune disease

For more such news and updates, please join our Group "Global Life Science Business Partnering" on LinkedIn.

Updates at Aagami:

  • New Client Win: Outreach and Business Development for a high growth US Med Tech company which has a promise to impact billions
  • New Client Win: Outlicensing of Korean client's Anti-Retinal-Disease and Anti-cancer Drugs
  • New Client Win - Partnering support to a US based bio-targeted nanomedicines company with world-wide exclusive rights to a novel and innovative drug-targeting platform technology
  • Aagami to attend BIO International Convention, 40+ meetings already scheduled with pre-defined agenda.